Yvonne A. Efebera MD MPH

Associate Professor, Dept of Internal Medicine, Division of Hematology, The Ohio State University.

500 Thomas LnColumbus, OH 43214
Phone+1 614-566-2500
Fax+1 614-293-4812

Dr. Efebera is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Efebera's full profile Already have an account?

Education & Training

Boston University Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
Cleveland Clinic FoundationResidency, Internal Medicine, 1998 - 2001
Pennsylvania State University College of MedicineClass of 1998

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

OH State Medical License 2000 - 2027
TX State Medical License 2008 - 2022
MA State Medical License 2004 - 2014
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014, 2016-2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
ACTIVE_NOT_RECRUITING
PHASE3
Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis
COMPLETED
PHASE3
Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)
COMPLETED
PHASE1, PHASE2

Publications & Presentations

PubMed

Comparative Efficacy of Belantamab Mafodotin in Combination With Bortezomib and Dexamethasone Versus Standards of Care in Patients With Third-Line or Later Relapsed/Re...
Joshua Richter, Yvonne Efebera, Habte Yimer, Pragya Shukla, Venediktos Kapetanakis
American Journal of Hematology. 2026-09-01
Phase I Trial of Venetoclax and BEAM Followed by Autologous Stem Cell Transplant for High-Risk Non-Hodgkin Lymphoma.
Joseph E Maakaron, Qiuhong Zhao, Jayalakshmi P Balakrishna, Marcin Puto, Sam Penza
Transplantation and Cellular Therapy. 2026-07-01
Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis.
Kitsada Wudhikarn, Lohith Gowda, Qiran Ye, Temitope Oloyede, Michael Martens
Transplantation and Cellular Therapy. 2026-06-27

Abstracts/Posters

The Effect of Cytogenetic Abnormalities on Organ Involvement and Survival in Patients with AL Amyloidosis
Yvonne A. Efebera, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Improvement in Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience
Yvonne A. Efebera, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...
Yvonne A. Efebera, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Aryl Hydrocarbon Receptor (AHR) Antagonism As a Transformative, Dual-Mechanism Novel Therapy for Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
The OP-104 Anchor Study: A Phase 1/2 Study of Safety and Efficacy of Melflufen and Dexamethasone in Combination with Either Bortezomib or Daratumumab in Patients with ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Lenalidomide and Vorinostat Maintenance after Autologous Transplant in Multiple Myeloma- Long Term Follow-up
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018